AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03866889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength
Description: In the performance of the squat exercise (Back Squat), the subjects will be standing, with an Olympic bar behind their neck, supported on both trapezoids, while the hands will help to hold and stabilize the bar, taking it from below.~For hamstring curl, the subject will be in the prone position, clinging to the backrest, with the legs under the arm that lifts the weight.~The deadlift exercise will be performed from the standing posture, holding the bar with your arms extended and the trunk straight, while your hands will hold the bar at the height and separation of the hips.~Finally, in the quadriceps chair the subject will find himself sitting with his back straight and supported on the back of the seat, while the legs will go under the arm that lifts the weight.
Study NCT03866889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal activity
Description: The subjects included in the control group will continue to perform the same strength training plan that they did before starting this one. The periodicity will be the same (4 days / week) and with the same intensity.
Study NCT03992365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Description: The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets.
Study NCT03992365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl
Description: The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.
Study NCT01499095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (Insulin glargine)
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Study NCT01499095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
Study NCT00113763 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care
Description: Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
Study NCT00113763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
Study NCT00522730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Duration : 5 days
Study NCT00522730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition
Description: Duration : 5 days
Study NCT01323517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab, Melphalan and Dactinomycin
Description: Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
Study NCT00685217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT Secur (Gynecare)
Description: Sling device for stress urinary incontinence
Study NCT00685217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT (Gynecare)
Description: Sling procedure for stress urinary incontinence
Study NCT03295292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
Study NCT03295292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: 50uL of commercially available fibrin sealant (Baxter, TISEEL)
Study NCT03295292 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: 50uL of commercially available fibrin sealant (Baxter, TISEEL)
Study NCT03442114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydroxyurea SDM Toolkit
Description: Implementation tools and visit decision aids
Study NCT03442114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Pocket Guide
Description: current hydroxyurea protocol and ASH pocket guide
Study NCT01731639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MSOME
Description: The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form > 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
Study NCT03015987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser activated irrigation
Description: diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
Study NCT03015987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diode laser activated irrigation
Description: diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
Study NCT02346656 — intervention group
Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study NCT03517540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison with monotherapy and different combination doses
Study NCT03517540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (CVC)
Description: Comparison with monotherapy and different combination doses
Study NCT02665793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBPCFC to peanut cookie
Study NCT02665793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose DBPCFC to peanut flour
Description: Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
Study NCT00769132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: niacin + laropiprant
Description: ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
Study NCT00769132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: niacin
Description: ER niacin 2 g tablet once daily for 7 days
Study NCT00769132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: laropiprant
Description: laropiprant 40 mg once daily for 7 days
Study NCT00769132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: matching placebo tablets for each of the interventions once daily for 7 days
Study NCT01971099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tribulus terrestris
Description: patients will use 750mg/day of tribulus terrestris
Study NCT01971099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will take one pill a day (the same shape of the drug)
Study NCT01065246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab
Description: 4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
Study NCT04220073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005 (recombinant humanized monoclonal antibody against IL-17A)
Description: JS005
Study NCT04220073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01028274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules, twice daily with meals for 12 weeks.
Study NCT01028274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Product 1
Description: Two capsules, twice daily with meals for 12 weeks.
Study NCT01028274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Product 2
Description: Two capsules, twice daily with meals for 12 weeks.
Study NCT00698009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
Study NCT00698009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
Study NCT00698009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Infusion
Description: Natural Killer Cell Infusion on Day 0.
Study NCT00698009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
Study NCT00698009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses.
Study NCT02742415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Hand Massage
Description: Caring Hand Massage is a hand massage therapy program with several steps and techniques.
Study NCT00823680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid for 4 weeks
Study NCT00823680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5027838
Description: 200mg po qd for 4 weeks
Study NCT00823680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5027838
Description: 50mg po bid for 4 weeks
Study NCT00823680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: 400mg po bid for 4 weeks
Study NCT00823680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5093151
Description: 10mg po bid for 4 weeks
Study NCT02505841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP block with Ropivacaine
Description: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
Study NCT02505841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curare
Description: Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
Study NCT02505841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curare
Description: Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
Study NCT03586778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
Study NCT03586778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
Study NCT03586778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
Study NCT03586778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercise
Description: Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
Study NCT03586778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic exercise
Description: Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
Study NCT01440608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
Study NCT01440608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
Study NCT01440608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose Zinc
Description: Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
Study NCT00685763 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation and chemotherapy
Description: Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses
Study NCT03757182 — intervention group
Intervention type: OTHER
Intervention: Wearable activity monitor
Description: Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
Study NCT03979586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser-assisted hyaluronic acid delivery
Description: The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
Study NCT04583592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
Study NCT04583592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
Study NCT01988194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
Study NCT03872908 — intervention group
Intervention type: DEVICE
Intervention: Chilled gloves
Description: Chilled glove for non-dominant hand (patients treated with paclitaxel)
Study NCT03872908 — intervention group
Intervention type: DEVICE
Intervention: Surgical gloves
Description: Surgical gloves (patients treated with oxaliplatine)
Study NCT00611780 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: tube voltage
Description: standard 120 kV
Study NCT00611780 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tube voltage
Description: reduced voltage of 100 kV
Study NCT00293605 — intervention group
Intervention type: PROCEDURE
Intervention: Total Hip Replacement
Description: Implantation of one of 3 stem designs
Study NCT04358822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: The umbilical cord will be clamped after specific time intervals
Study NCT02665793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-dose DBPCFC to peanut butter
Description: Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
Study NCT01431079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine acceptability
Description: One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
Study NCT01431079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV vaccine acceptability
Description: One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
Study NCT03119870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Train
Description: Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
Study NCT03119870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
Study NCT03119870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
Study NCT02401269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT01140425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00232798
Description: 600 mg oral solution once daily x 7 days
Study NCT01140425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00232798
Description: 300 mg oral solution once daily x 7 days
Study NCT01140425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution once daily x 7 days
Study NCT02108132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellular therapy
Description: bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
Study NCT02108132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cellular therapy
Description: Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen